Rheumatoid Arthritis RA
Conditions
Brief summary
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with moderate to severe RA.
Interventions
DRUGEfavaleukin alfa
Efavaleukin alfa administered as a subcutaneous injection.
DRUGPlacebo
Placebo administered as a subcutaneous injection.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 to ≤ 70 years of age at screening. * A diagnosis of RA consistent with the 1987 or 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria. * Active RA defined as: Phase 1b: DAS-28-CRP \> 2.6 at screening. The 28-joint count consists of the finger joints excluding the distal interphalangeal joints, the wrists, elbows, shoulders, and knees. Phase 2a: ≥ 6 swollen joints (based on 66-joint count) and ≥ 6 tender joints (based on 68-joint count) at screening and baseline. The distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility. Additionally, C-reactive protein (CRP) must be greater than the upper limit of normal (ULN) per the central laboratory at screening. * Receiving treatment with methotrexate for ≥ 12 weeks and on a stable dose ≥ 15 mg weekly for ≥ 8 weeks prior to day 1. A lower methotrexate dose is acceptable (but no lower than 10 mg weekly) if it is the highest tolerated dose and gastrointestinal or hematologic toxicity at doses ≥ 15 mg weekly is documented by the investigator. * Receiving treatment with folic or folinic acid per investigator judgment or according to local standard of care. * Phase 1b only: Subject may be receiving a stable dose of leflunomide, sulfasalazine, hydroxychloroquine, minocycline in combination with methotrexate and the dose must be stable for ≥ 8 weeks prior to day 1. * Subject may be receiving a stable dose of prednisone ≤ 10mg daily or other equivalent corticosteroid dose and the dose must be stable for ≥ 2 weeks prior today 1. * Phase 1b only. Normal or clinically acceptable electrocardiogram (ECG) values (12-lead reporting ventricular rate and PR, QRS, QT and QTc interval) at screening and baseline based on opinion of the investigator. * Immunizations (tetanus, diphtheria, pertussis, seasonal influenza \[during flu season\], and pneumococcal \[polysaccharide\] vaccinations) up to date per local standards as determined by the investigator.
Exclusion criteria
* Class IV RA according to ACR revised response criteria * Diagnosis of Felty's Syndrome (RA, splenomegaly and granulocytopenia). * Prosthetic joint infection within 3 years of screening or native joint infection within 1 year prior to screening. * Active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to day 1 OR presence of serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to day 1. * Known history of active tuberculosis. * Positive test for tuberculosis during screening defined as either: positive purified protein derivative (PPD) (≥ 5 mm of induration at 48 to 72 hours after test is placed) OR positive Quantiferon test: a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative Quantiferon test and negative chest x ray; a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or a positive or indeterminate Quantiferon test are allowed if they have ALL of the following at screening: no symptoms per tuberculosis or sheet provided by Amgen; document history of a completed course of adequate prophylaxis(completed treatment for latent tuberculosis per local standard of care prior to the start of investigational product); no known exposure to a case of active tuberculosis after most recent prophylaxis; negative chest X-ray. * Positive for hepatitis B surface antigen, hepatitis B core antibody (confirmed by hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction \[PCR\] test) or detectable hepatitis C virus ribonucleic acid (RNA) by PCR (screening is generally done by hepatitis C antibody \[HepCAb\], followed by hepatitis C virus RNA by PCR if HepCAb is positive). A history of hepatitis B vaccination without history of hepatitis B is allowed. * Phase 1b only: Positive for Human Immunodeficiency Virus (HIV) at screening or known to be HIV positive. Phase 2a only: Known history of HIV * Phase 1b only: Positive drug or alcohol urine test for illicit drugs at screening. Prescription medications detected by the drug test are allowed if they are being taken under the direction of a physician. * Presence of one or more significant concurrent medical conditions per investigator judgment, including but not limited to the following: poorly controlled diabetes or hypertension; chronic kidney disease stage IIIb, IV, or V; symptomatic heart failure (New York Heart Association class II, III, or IV); myocardial infarction or unstable angina pectoris within the past 12 months prior to randomization; severe chronic pulmonary disease (eg, requiring oxygen therapy); multiple sclerosis or any other demyelinating disease; major chronic inflammatory disease or connective tissue disease other than RA (eg, systemic lupus erythematosus with the exception of secondary Sjögren's syndrome). * Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years. * History of alcohol or substance abuse within 6 months of screening * Phase 1b only: Current smoker, and/or use of any nicotine or tobacco containing products within the last 6 months prior to day 1. These types of products include but are not limited to: snuff, chewing tobacco, cigars, electronic cigarettes, cigarettes, pipes, or nicotine patches. * Phase 1b only: Subject unwilling to limit alcohol consumption to ≤ 1 drink of alcohol per day and ≤ 3 drinks per week for the duration of the study, where a drink is equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits. Phase 1b only: Unwilling or unable to abstain from alcohol consumption within 48 hours prior to each visit (including screening). * Subjects who have received intra-articular or systemic corticosteroid injections for treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4 weeks prior to screening. * Currently receiving or had treatment with cyclophosphamide, chlorambucil, nitrogen mustard, or any other alkylating agent ≤ 6 months prior to day 1. * Prior treatment with more than a total of 3 therapies that include biologic disease modifying anti-rheumatic drug (DMARDs) or oral synthetic DMARDs (such as tofacinitib, baricitinib). Prior treatment consists of at least 4 doses of a given therapy where the doses were given solely for treatment of RA disease. Prior therapies must not have been used within the following time periods: * ≤ 4 weeks prior to day 1 for etanercept and anakinra * ≤ 6 months for rituximab * ≤ 2 weeks for oral janus kinase inhibitors * ≤ 9 weeks prior to day 1 for all therapies not listed above * Currently receiving or had treatment with any of the following ≤ 12 weeks prior to day 1: * azathioprine * cyclosporine * gold * mycophenolate mofetil * Prosorba column * Tacrolimus * Phase 2a only: Currently receiving or had treatment with leflunomide ≤ 12 weeks prior to day 1 unless an active washout with cholestyramine has been performed. * Phase 2a only: Currently receiving or had treatment with any of the following ≤ 4 weeks prior to day 1: * hydroxychloroquine * sulfasalazine * minocycline * oral janus kinase inhibitor (eg, tofacitinib, baricitinib) * intra-articular, intramuscular or intravenous corticosteroids, including adrenocorticotropic hormone * intra-articular hyaluronic acid injections * live vaccines -- For Phase 2 only: * Unstable dose of non-steroidal anti-inflammatory drugs (NSAID), acetaminophen, and/or analgesics which is taken on an unscheduled basis (ie, not daily or scheduled every certain number of hours) and/or initiated \<4 weeks prior to day 1. * Received the following within 12 hours prior to screening or day 1: acetaminophen, NSAIDs, tramadol, and/or any narcotic analgesics such as but not limited to hydrocodone, codeine, tramadol, propoxyphene and/or oxycodone (unless in the form of oxycontin). Subject has taken oxycontin within 24 hours prior to screening or day 1. * Phase 1b only: Received any herbal medicines (eg St John's wort),or non-vitamin dietary supplements (eg, magnesium) with the exception of calcium within 4 weeks prior to day 1. * Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded. * Presence of laboratory abnormalities at screening including the following: * Aspartate aminotransferase (AST) or alanine amino transferase (ALT) at screening \> 1.5X upper limit of normal (ULN) * Serum total bilirubin (TBL) ≥ 1.5 mg/dL (≥ 26 μmol/L) * Hemoglobin ≤ 10.5 g/dL(≤105 g/L) * Platelet count \< 100,000/mm\^3 (\<100 x 10\^9/L) * White blood cell count \< 2,500 cells/mm\^3 (2.5 x 10\^9/L) * Absolute neutrophil count (ANC) \< 1,000/mm\^3 (1.0 x 10\^9/L) * Calculated glomerular filtration rate of ≤ 50 mL/min/1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula * Any other laboratory abnormality, which, in the opinion of the investigator, poses a safety risk, will prevent the subject from completing the study, will interfere with the interpretation of the study results, or might cause the study to be detrimental to the subject. * Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 weeks after the last dose of investigational product. * Females of child-bearing potential with a positive pregnancy test (assessed by a serum pregnancy test at screening and a urine pregnancy test at baseline). * Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 6 weeks after the last dose of investigational product. * Subject has known sensitivity to any of the products or components to be administered during dosing. * Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments \[COAs\]) to the best of the subject and investigator's knowledge. * History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | TEAEs were events with an onset after the administration of the first dose of study treatment. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE). Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated. Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria: * Results in death (fatal) * Immediately life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other medically important serious event |
| Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported. |
| Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated. |
| Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs) | Baseline up to end of treatment maximum of 12 weeks | Any changes in ECG parameters that were deemed clinically significant by the investigator were reported. |
| Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12 | Baseline and Week 12 | ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria: * physician global assessment of disease activity (PGA) * subject global assessment of disease activity (SGA) * patient global assessment of joint pain * subject self-assessment of disability (HAQ-DI) * C-Reactive Protein (CRP) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported. |
| Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported. |
| Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | Baseline up to Week 12 | Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported. |
| Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12 | Baseline and Week 12 | ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria: * physician global assessment of disease activity (PGA) * subject global assessment of disease activity (SGA) * patient global assessment of joint pain * subject self-assessment of disability (HAQ-DI) * C-Reactive Protein (CRP) |
| Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12 | Baseline and Week 12 | Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity. |
| Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12 | Baseline and Week 12 | Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity. |
| Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (pre-dose), 6 and 12 hours post-dose, and days 2, 3, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and Day 85 (pre-dose), 6 and 12 hours post-dose and days 86, 87, 88, 92, 99, 113 and 127 | A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00. |
| Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated. |
| Phase 2a: Efavaleukin Alfa Serum Concentration | Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12 | A summary of mean serum concentrations of Efavaleukin alfa over time. |
| Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12 | — |
| Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12 | — |
| Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa | Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12 | — |
| Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up) | TEAEs were events with an onset after the administration of the first dose of study treatment. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE). |
| Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127 | — |
| Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127 | — |
| Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose | Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11 and 15, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92 and 99 | AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A. |
| Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose | Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4 and 8, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Day 92 | AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B. |
Countries
Bulgaria, Germany, Poland, Spain, United States
Participant flow
Recruitment details
Participants in phase 1b were to be enrolled into 1 of 4 planned dosing cohorts and randomized in a 3:1 ratio to receive Efavaleukin alfa or placebo according to 1 of 2 dosing schedules; A (less frequent) and B (more frequent).
Pre-assignment details
Enrollment of the phase 1b part of this study was stopped as of 30 September 2019, due to data that suggested that there is not sufficient benefit-risk for the use of Efavaleukin alfa plus standard of care therapy in this study population. The study was terminated prior to the enrollment of any participants into phase 1b Cohort 4 and phase 2a cohorts.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b: Placebo Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A \[less frequent\] or schedule B \[more frequent\]). | 8 |
| Phase 1b: Efavaleukin Alfa Cohort 1 A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks. | 6 |
| Phase 1b: Efavaleukin Alfa Cohort 2 A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks. | 11 |
| Phase 1b: Efavaleukin Alfa Cohort 3 A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks. | 11 |
| Total | 36 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Decision by Sponsor | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 2 | 5 | 5 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Cohort 3 | Total |
|---|---|---|---|---|---|
| Age, Continuous | 46.4 years STANDARD_DEVIATION 12.1 | 57.8 years STANDARD_DEVIATION 8.4 | 53.1 years STANDARD_DEVIATION 10.7 | 51.4 years STANDARD_DEVIATION 15.3 | 51.9 years STANDARD_DEVIATION 12.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 6 Participants | 9 Participants | 10 Participants | 32 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black or African American | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 6 Participants | 5 Participants | 11 Participants | 11 Participants | 33 Participants |
| Sex: Female, Male Female | 4 Participants | 6 Participants | 9 Participants | 8 Participants | 27 Participants |
| Sex: Female, Male Male | 4 Participants | 0 Participants | 2 Participants | 3 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 6 | 0 / 11 | 0 / 11 |
| other Total, other adverse events | 3 / 8 | 5 / 6 | 11 / 11 | 11 / 11 |
| serious Total, serious adverse events | 0 / 8 | 0 / 6 | 1 / 11 | 0 / 11 |
Outcome results
Primary
Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)
Any changes in ECG parameters that were deemed clinically significant by the investigator were reported.
Time frame: Baseline up to end of treatment maximum of 12 weeks
Population: The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs) | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs) | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs) | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs) | 0 Participants |
Primary
Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests
Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated.
Time frame: Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests | 0 Participants |
Primary
Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs
Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.
Time frame: Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs | 0 Participants |
Primary
Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
TEAEs were events with an onset after the administration of the first dose of study treatment. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE). Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated. Serious adverse events (SAEs) were defined as meeting at least 1 of the following criteria: * Results in death (fatal) * Immediately life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other medically important serious event
Time frame: Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: The safety analysis set: All participants who received at least 1 dose of investigational product. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs | 3 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 2 TEAEs | 2 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 3 TEAEs | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 4 TEAEs | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | SAEs | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs leading to discontinuation of study treatment | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Life-threatening TEAEs | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Fatal TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs leading to discontinuation of study treatment | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | SAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 2 TEAEs | 3 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Fatal TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Life-threatening TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 4 TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 3 TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs | 5 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Life-threatening TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 3 TEAEs | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 4 TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | SAEs | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs leading to discontinuation of study treatment | 7 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Fatal TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs | 11 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 2 TEAEs | 8 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 3 TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 4 TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Grade ≥ 2 TEAEs | 8 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs | 11 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | SAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Fatal TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Life-threatening TEAEs | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAEs leading to discontinuation of study treatment | 3 Participants |
Primary
Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12
ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria: * physician global assessment of disease activity (PGA) * subject global assessment of disease activity (SGA) * patient global assessment of joint pain * subject self-assessment of disability (HAQ-DI) * C-Reactive Protein (CRP)
Time frame: Baseline and Week 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose
AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A.
Time frame: Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11 and 15, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92 and 99
Population: The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose | First dose (Day 1) | 167 hr*ng/mL | Standard Deviation 60.9 |
| Phase 1b: Placebo | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose | Last dose (Day 85) | 282 hr*ng/mL | Standard Deviation 207 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose | Last dose (Day 85) | NA hr*ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose | First dose (Day 1) | 1570 hr*ng/mL | Standard Deviation 859 |
Secondary
Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose
AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B.
Time frame: Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4 and 8, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Day 92
Population: The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose | First dose (Day 1) | 315 hr*ng/mL | Standard Deviation 239 |
| Phase 1b: Placebo | Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose | Last dose (Day 85) | 195 hr*ng/mL | Standard Deviation 264 |
Secondary
Phase 1b: Efavaleukin Alfa Serum Concentrations
A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00.
Time frame: Day 1 (pre-dose), 6 and 12 hours post-dose, and days 2, 3, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and Day 85 (pre-dose), 6 and 12 hours post-dose and days 86, 87, 88, 92, 99, 113 and 127
Population: The pharmacokinetic (PK) analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 11 | 0.0230 ng/mL | Standard Deviation 0.0514 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 57 | 0.0368 ng/mL | Standard Deviation 0.0735 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 64 | 0.336 ng/mL | — |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 71 | 0.0635 ng/mL | — |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 36 | 0.0644 ng/mL | Standard Deviation 0.144 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 78 | 0.154 ng/mL | Standard Deviation 0.267 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (pre-dose) | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (pre-dose) | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 92 | 0.113 ng/mL | — |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 99 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (12 hours post-dose) | 4.00 ng/mL | Standard Deviation 2.05 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 113 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (12 hours post-dose) | 2.43 ng/mL | Standard Deviation 0.867 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (6 hours post-dose) | 1.35 ng/mL | Standard Deviation 0.795 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 2 | 2.59 ng/mL | Standard Deviation 0.875 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 86 | 3.60 ng/mL | Standard Deviation 2.07 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 3 | 1.70 ng/mL | Standard Deviation 0.85 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 4 | 0.727 ng/mL | Standard Deviation 0.277 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (6 hours post-dose) | 2.41 ng/mL | Standard Deviation 1.56 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 8 | 0.0555 ng/mL | Standard Deviation 0.0924 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 87 | 2.10 ng/mL | Standard Deviation 1.15 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 15 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 22 | 0.0830 ng/mL | Standard Deviation 0.144 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 88 | 1.48 ng/mL | Standard Deviation 0.623 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 29 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 43 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 127 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Placebo | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 50 | 0.205 ng/mL | Standard Deviation 0.304 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 50 | 0.105 ng/mL | Standard Deviation 0.21 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 127 | 0.00 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 11 | 0.0115 ng/mL | Standard Deviation 0.0364 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 57 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 29 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 2 | 22.0 ng/mL | Standard Deviation 11.5 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 64 | 0.212 ng/mL | Standard Deviation 0.424 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (6 hours post-dose) | 7.67 ng/mL | Standard Deviation 8.01 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 87 | 4.39 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 71 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 88 | 1.01 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 3 | 18.6 ng/mL | Standard Deviation 9.16 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 78 | 0.355 ng/mL | Standard Deviation 0.614 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 36 | 0.102 ng/mL | Standard Deviation 0.203 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 86 | 12.3 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (pre-dose) | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (12 hours post-dose) | 12.9 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 15 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 4 | 7.65 ng/mL | Standard Deviation 5.85 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 92 | 0.00 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (pre-dose) | 0.0 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (6 hours post-dose) | 5.91 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 99 | 0.00 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 43 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 8 | 0.108 ng/mL | Standard Deviation 0.146 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 113 | 0.00 ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 22 | 0.0703 ng/mL | Standard Deviation 0.112 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (12 hours post-dose) | 14.6 ng/mL | Standard Deviation 12.1 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 127 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (pre-dose) | 0.0578 ng/mL | Standard Deviation 0.0958 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (6 hours post-dose) | 1.92 ng/mL | Standard Deviation 2.64 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 85 (12 hours post-dose) | 2.92 ng/mL | Standard Deviation 4.03 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 86 | 2.97 ng/mL | Standard Deviation 4.48 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 87 | 1.87 ng/mL | Standard Deviation 2.43 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 29 | 0.217 ng/mL | Standard Deviation 0.344 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (6 hours post-dose) | 2.13 ng/mL | Standard Deviation 2.98 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (12 hours post-dose) | 4.09 ng/mL | Standard Deviation 4.7 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 2 | 5.44 ng/mL | Standard Deviation 5.09 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 3 | 3.65 ng/mL | Standard Deviation 3.13 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 4 | 2.36 ng/mL | Standard Deviation 2.84 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 8 | 0.0284 ng/mL | Standard Deviation 0.0624 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 11 | 0.930 ng/mL | Standard Deviation 0.78 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 15 | 0.107 ng/mL | Standard Deviation 0.15 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 22 | 0.235 ng/mL | Standard Deviation 0.373 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 36 | 0.239 ng/mL | Standard Deviation 0.425 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 43 | 0.104 ng/mL | Standard Deviation 0.275 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 50 | 0.122 ng/mL | Standard Deviation 0.322 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 57 | 0.0886 ng/mL | Standard Deviation 0.234 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 64 | 0.0294 ng/mL | Standard Deviation 0.0657 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 71 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 78 | 0.0508 ng/mL | Standard Deviation 0.0819 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 88 | 0.903 ng/mL | Standard Deviation 1.17 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 92 | 0.0953 ng/mL | Standard Deviation 0.115 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 99 | 0.110 ng/mL | Standard Deviation 0.268 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 113 | 0.00 ng/mL | Standard Deviation 0 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Efavaleukin Alfa Serum Concentrations | Day 1 (pre-dose) | 0.00 ng/mL | Standard Deviation 0 |
Secondary
Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa
Time frame: Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127
Population: The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | First dose (Day 1) | 2.66 ng/mL | Standard Deviation 0.852 |
| Phase 1b: Placebo | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | Last dose (Day 85) | 4.00 ng/mL | Standard Deviation 2.05 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | First dose (Day 1) | 23.0 ng/mL | Standard Deviation 11.2 |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | Last dose (Day 85) | NA ng/mL | — |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | Last dose (Day 85) | 3.22 ng/mL | Standard Deviation 4.35 |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa | First dose (Day 1) | 5.71 ng/mL | Standard Deviation 5.1 |
Secondary
Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies
Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported.
Time frame: Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 binding antibodies. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-AMG 592 antibody positive post-baseline with a negative or no result at baseline | 2 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-AMG 592 antibody positive post-baseline with a negative or no result at baseline | 3 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-AMG 592 antibody positive post-baseline with a negative or no result at baseline | 6 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-AMG 592 antibody positive post-baseline with a negative or no result at baseline | 5 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies | Binding anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 1 Participants |
Secondary
Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies
The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported.
Time frame: Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: All participants who received at least 1 dose of investigational product and had a baseline and at least 1 post-baseline result. Only participants who tested positive for anti-Efavaleukin alfa antibodies were analyzed for presence of anti-IL2 neutralizing antibodies. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 0 Participants |
| Phase 1b: Placebo | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-AMG 592 antibodies positive post-baseline with a negative or no result at baseline | 2 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 0 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-AMG 592 antibodies positive post-baseline with a negative or no result at baseline | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-AMG 592 antibodies positive post-baseline with a negative or no result at baseline | 7 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 1 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-AMG 592 antibodies positive post-baseline with a negative or no result at baseline | 5 Participants |
| Phase 1b: Efavaleukin Alfa Cohort 3 | Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies | Neutralizing anti-IL2 antibody positive post-baseline with a negative or no result at baseline | 1 Participants |
Secondary
Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa
Time frame: Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127
Population: The PK analysis set: All participants who received at least one dose of Efavaleukin alfa and had at least one quantifiable PK sample collected. Only participants with PK data available for analysis are presented. Only cohorts with enrolled participants are included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase 1b: Placebo | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | First dose (Day 1) | 18 hours |
| Phase 1b: Placebo | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | Last dose (Day 85) | 12 hours |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | First dose (Day 1) | 24 hours |
| Phase 1b: Efavaleukin Alfa Cohort 1 | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | Last dose (Day 85) | 30 hours |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | First dose (Day 1) | 24 hours |
| Phase 1b: Efavaleukin Alfa Cohort 2 | Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa | Last dose (Day 85) | 12 hours |
Secondary
Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa
Time frame: Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12
Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity.
Time frame: Baseline and Week 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12
Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity.
Time frame: Baseline and Week 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Efavaleukin Alfa Serum Concentration
A summary of mean serum concentrations of Efavaleukin alfa over time.
Time frame: Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa
Time frame: Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12
ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria: * physician global assessment of disease activity (PGA) * subject global assessment of disease activity (SGA) * patient global assessment of joint pain * subject self-assessment of disability (HAQ-DI) * C-Reactive Protein (CRP)
Time frame: Baseline and Week 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
| Arm | Measure | Group | Value |
|---|---|---|---|
| Unknown | Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12 | ACR 50 | — |
| Unknown | Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12 | ACR 70 | — |
Secondary
Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests
Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated.
Time frame: Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs
Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.
Time frame: Baseline up to Week 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
TEAEs were events with an onset after the administration of the first dose of study treatment. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.
Secondary
Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa
Time frame: Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12
Population: No data is available for phase 2a. Study was terminated prior to any participants enrolling in phase 2a.